Why Might a Second TURBT Be Needed After Bladder Tumour Resection?

Quick answer

Repeat TURBT is another resection to look for tumour remaining at the original site and clarify staging. It is particularly considered for T1 tumours and when the first resection was incomplete or its completeness is uncertain. A recommendation for repeat TURBT does not, by itself, mean the first operation was performed incorrectly.

What do TUR-M, TURBT and re-TURBT mean?

TUR-M and TURBT refer to removal of a bladder tumour through the urethra. The tissue is sent for pathology. Re-TURBT means a planned second resection for the same disease. It is different from cystectomy, which removes the bladder, and from TURP, which treats prostate tissue.

Who may be offered another resection?

• When the first TURBT did not remove all the tumour or complete removal is uncertain.
• When pathology identifies a T1 tumour.
• When detrusor muscle is absent from the first sample, while taking account of the exceptions for low-grade Ta and primary CIS.

When a second TURBT is indicated, the EAU guideline recommends an interval of two to six weeks after the first procedure. This is not an automatic appointment timetable for everyone: recovery, infection and anaesthetic assessment affect the individual plan. Discuss timing with the treatment team if an appointment will be delayed.

References for this section: EAU. Non-muscle-invasive Bladder Cancer: Diagnosis — TURBT, second resection and pathology report.

What can another procedure change if the tumour was removed?

Removing the visible tumour and excluding microscopic disease are not the same thing. The previous tumour bed is reassessed at the second procedure. If the new pathology shows deeper involvement, treatment may change; finding no tumour also informs the next plan. A clear result does not, by itself, prove either procedure was unnecessary.

What does research show about repeat TURBT?

In the randomised trial by Divrik and colleagues involving newly diagnosed T1 disease, repeat TURBT could identify residual tumour or a higher stage even when the first removal appeared complete. Re-resection therefore does more than correct a visible incomplete removal. Nevertheless, one trial cannot be applied unchanged to every stage and risk group.

The systematic review by Cumberbatch and colleagues found wide variation between centres in reported residual-tumour and upstaging rates. Differences in patient selection, initial surgery and study methods mean that these figures are not personal probabilities. The shared clinical question is whether the first specimen adequately established the extent of disease.

References for this section: Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010;58(2):185-90. Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018;73(6):925-933.

How can the new pathology change the treatment pathway?

Finding no tumour in the new sample is encouraging, but it does not by itself cancel surveillance required by an initially high-risk report. Conversely, a higher stage cannot simply be interpreted as growth over a few weeks: re-evaluation may reveal an area that the first specimen did not identify.

References for this section: Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010;58(2):185-90. Compérat E, Tsuzuki T, Baydar DE, et al. Urinary Tract Carcinoma Histopathology Reporting Guide — Biopsy and Transurethral Resection Specimen. 2nd ed. International Collaboration on Cancer Reporting; 2025.

Is only the previous tumour site examined?

The previous tumour bed is important, but other bladder areas and any new suspicious findings are also assessed. The origin of each tissue sample should be communicated accurately to pathology. Bring the first operation report, any available images and the complete pathology report. Whether adequate muscle was sampled cannot be inferred from catheter duration or the amount of blood in the urine.

References for this section: EAU. Non-muscle-invasive Bladder Cancer: Diagnosis — TURBT, second resection and pathology report. Compérat E, Tsuzuki T, Baydar DE, et al. Urinary Tract Carcinoma Histopathology Reporting Guide — Biopsy and Transurethral Resection Specimen. 2nd ed. International Collaboration on Cancer Reporting; 2025.

What should be discussed about preparation and recovery?

Anaesthetic suitability, urinary symptoms and medicines are reviewed beforehand. Do not stop blood thinners on your own; the surgeon and relevant clinician should plan this together. The need for a catheter or bladder irrigation depends on bleeding and the extent of resection. The same hospital stay or return-to-work date cannot be promised to everyone.

Temporary burning or blood in the urine may occur. Inability to pass urine, heavy bleeding with clots, fever or increasing pain requires contact with the treatment team or urgent assessment. Your individual discharge instructions take priority over a general online list.

References for this section: Leeds Teaching Hospitals NHS Trust. T.U.R.B.T. (Trans-Urethral Resection of Bladder Tumour). Cancer Research UK. Trans urethral resection of bladder tumour (TURBT).

Is repeat TURBT the same as a follow-up cystoscopy?

No. Follow-up cystoscopy looks inside the bladder; a biopsy or another procedure may be arranged if needed. Re-TURBT aims to remove tissue for pathological reassessment. If a second look is proposed, ask whether this means an examination cystoscopy or another resection under anaesthesia.

Will BCG or another treatment be needed afterwards?

Repeat TURBT does not necessarily complete all treatment. The final pathology and risk assessment guide discussion of intravesical medicines, BCG, surveillance or more extensive treatment. If muscle invasion is found, the plan for non-muscle-invasive disease is not simply continued unchanged: staging and treatment are reconsidered.

Can starting BCG immediately replace repeat TURBT?

BCG and re-resection answer different needs: BCG is intravesical treatment, whereas repeat TURBT obtains tissue to assess stage and residual disease. If re-resection is indicated, moving drug treatment forward does not remove the need for that information. The team plans which question to answer first and when intravesical treatment can safely begin.

Cancelling because urinary symptoms improved, or substituting ultrasound alone, is not equivalent to the planned resection. If you are worried about another procedure, explain whether the concern is anaesthesia, pain, bleeding or having another operation. This makes discussion of benefits, risks and your circumstances more specific.

References for this section: EAU. Non-muscle-invasive Bladder Cancer: Diagnosis — TURBT, second resection and pathology report. Leeds Teaching Hospitals NHS Trust. T.U.R.B.T. (Trans-Urethral Resection of Bladder Tumour).

Four questions for the results appointment

• Why is repeat TURBT recommended in my case?
• Did the first sample include the main bladder muscle?
• How could the new pathology change treatment?
• When will the results appointment and next follow-up take place?

Frequently asked questions

Does every bladder tumour need a second TURBT?

No. The need depends on the completeness of the first procedure and pathology. A small low-grade Ta tumour is not assessed in the same way as T1 disease.

Is repeat TURBT the same as the cancer coming back?

No. A planned staging or completion resection shortly after the first procedure is different from a recurrent tumour detected later during follow-up.

Does a recommendation for repeat TURBT definitely mean a poor outcome?

No. It identifies a need for further assessment. An individual outcome or life expectancy cannot be inferred before the new findings are known.

Sources

1. European Association of Urology. EAU. Non-muscle-invasive Bladder Cancer: Diagnosis — TURBT, second resection and pathology report [Internet]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis
2. Leeds Teaching Hospitals NHS Trust. T.U.R.B.T. (Trans-Urethral Resection of Bladder Tumour) [Internet]. Available from: https://www.leedsth.nhs.uk/patients/resources/t-u-r-b-t-trans-urethral-resection-of-bladder-tumour/
3. Cancer Research UK. Trans urethral resection of bladder tumour (TURBT) [Internet]. Available from: https://www.cancerresearchuk.org/about-cancer/bladder-cancer/treatment/non-muscle-invasive/trans-urethral-removal-tumour
4. National Cancer Institute. Bladder Cancer Diagnosis [Internet]. Available from: https://www.cancer.gov/types/bladder/diagnosis
5. European Association of Urology. EAU. Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC [Internet]. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/followup-of-patients-with-nmibc
6. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010;58(2):185-90. doi:10.1016/j.eururo.2010.03.007 · PubMed
7. Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018;73(6):925-933. doi:10.1016/j.eururo.2018.02.014 · PubMed
8. Compérat E, Tsuzuki T, Baydar DE, et al. Urinary Tract Carcinoma Histopathology Reporting Guide — Biopsy and Transurethral Resection Specimen. 2nd ed. International Collaboration on Cancer Reporting; 2025 [Internet]. Available from: https://www.iccr-cancer.org/datasets/published-datasets/urinary-male-genital/ut-biopsy-and-tr/